Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 18, 2024$0.85
P/E Ratio
N/A
Market Cap
$144.19M
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Overview
Trading Information
Company